Home Special Topics Technology Offerings Content

DenCe-ctive - Use of autologous Thrombocytes for induction of Dendritic Cell activity

next article

04.07.2008

The therapeutic use of dendritic cells in vaccination therapy requires prior activation of these immune cells. The invention exploits the ability of stimulated thrombocytes to activate dendritic cells ex vivo thereby offering the unique possibility of autologous activation. Immune therapy using activated dendritic cells is a well established approach used for various therapies including cancer vaccination strategies. An enormous market potential is expected. The invention provides the first method triggering an autologous maturation of dendritic cells into potent antigen presenting cells. Thus, the method constitutes a highly efficacious approach for inducing T-cell responses. The simple and efficient activation strategy is strikingly easy to handle and compatible with established immunotherapy protocols.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 0

Contact
Dipl.-Ing. Alfred Schillert

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

info@technologieallianz.de | Source: TechnologieAllianz e.V.
Further information: www.technologieallianz.de/angebote.php?sort=sag&id=0919&lang=en
www.technologieallianz.de

next article